Is the Optimal Timing First Complete Remission for Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma?

Uncu Ulu, Bahar; Yiğenoğlu, Tuğçe Nur; Altuntas, Fevzi; ŞAHİN, DERYA; Kızıl Çakar, Merih; DAL, MEHMET SINAN

doi:10.4274/nkmj.galenos.2021.08108

Is the Optimal Timing First Complete Remission for Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma?

Bahar ULU, (Sağlık Bilimleri Üniversitesi Türkiye, Abdurrahman Yurtaslan Ankara Onkoloji Eğitim ve Araştırma Hastanesi, Hematoloji Kliniği, Kemik İlik Ekimi Ünitesi, Ankara, Türkiye)

Derya ŞAHİN, (Sağlık Bilimleri Üniversitesi Türkiye, Abdurrahman Yurtaslan Ankara Onkoloji Eğitim ve Araştırma Hastanesi, Hematoloji Kliniği, Kemik İlik Ekimi Ünitesi, Ankara, Türkiye)

Tuğçe Nur YİĞENOĞLU, (Sağlık Bilimleri Üniversitesi Türkiye, Abdurrahman Yurtaslan Ankara Onkoloji Eğitim ve Araştırma Hastanesi, Hematoloji Kliniği, Kemik İlik Ekimi Ünitesi, Ankara, Türkiye)

Merih KIZIL ÇAKAR, (Sağlık Bilimleri Üniversitesi Türkiye, Abdurrahman Yurtaslan Ankara Onkoloji Eğitim ve Araştırma Hastanesi, Hematoloji Kliniği, Kemik İlik Ekimi Ünitesi, Ankara, Türkiye)

Mehmet DAL, (Sağlık Bilimleri Üniversitesi Türkiye, Abdurrahman Yurtaslan Ankara Onkoloji Eğitim ve Araştırma Hastanesi, Hematoloji Kliniği, Kemik İlik Ekimi Ünitesi, Ankara, Türkiye)

Fevzi ALTUNTAŞ (Sağlık Bilimleri Üniversitesi Türkiye, Abdurrahman Yurtaslan Ankara Onkoloji Eğitim ve Araştırma Hastanesi, Hematoloji Kliniği, Kemik İlik Ekimi Ünitesi, Ankara, Türkiye)

Namık Kemal Tıp Dergisi

1 0

Yıl: 2021 Cilt: 9 Sayı: 2 Sayfa Aralığı: 207 - 212 Metin Dili: İngilizce DOI: 10.4274/nkmj.galenos.2021.08108 İndeks Tarihi: 12-10-2021

Is the Optimal Timing First Complete Remission for Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma?

Öz:

Aim: Outcome for most patients with peripheral T-cell lymphomas (PTCLs) is poor, with low response rates and short durations of remission. We aimto analyze the outcome of PTCL patients who underwent autologous stem cell transplantation (ASCT) at our center and we researched whether firstcomplete remission (CR) was the optimal timing for ASCT in patients with PTCL.Materials and Methods: The data of PTCL patients who underwent ASCT between January 2010 and December 2020 at our center wereretrospectively analyzed.Results: Twenty-five patients with PTCL underwent ASCT. The median ASCT age was 44 years (range: 19-68). 68% of the patients were performedupfront ASCT after the first CR; 32% of the patients underwent ASCT after relapse or refractory (R/R) disease. The median follow-up time fromdiagnosis was 40 months (13-144 months). The five-year PFS and OS were 50.8% and 55.7%, respectively. Five-year OS was 82.4% in the up-frontASCT group, while the five-year OS was 15.6% in the R/R patients (p=0.019). The median OS was 25 months [95% confidence interval (CI): 0-50.4]in patients who had CR2, while it was 13 months (95% CI: 0-35) in patients who had PR before ASCT (p=0.03). According to subtypes of PTCL, OSand PFS were not statistically different in all groups (p=0.96 and p=0.79, respectively).Conclusion: Even the prognosis is poor in patients with PTCL, Overall survival was significantly longer among the upfront ASCT group. Patientsshould be consolidated with ASCT in the first CR, and relapse should not be waited to perform ASCT.

Anahtar Kelime:

Periferik T Hücreli Lenfoma Hastarında Otolog Kök Hücre Nakli için Uygun Zamanlama İlk Tam Remisyon mudur?

Öz:

Amaç: Periferik T hücre lenfomalı (PTHL) çoğu hasta için sonuçlar, düşük yanıt oranları ve kısa remisyon süreleri ile kötü seyreder. Merkezimizde otolog kök hücre transplantasyonu (OKHN) yapılan PTHL hastalarının sonuçlarının analizini ve PTHL’li hastalarda OKHN için ilk tam remisyonun (TR) optimal zamanlama olup olmadığını araştırmayı amaçladık. Gereç ve Yöntem: Merkezimizde Ocak 2010 ile Aralık 2020 arasında OKHN uygulanan PTHL hastalarının verileri geriye dönük olarak incelendi. Bulgular: PTHL’li 25 hastaya OKHN uygulandı. Ortanca OKHN yaşı 44 (19-68) yıl olarak saptandı. Hastaların %68’ine ilk TR’den sonra upfront OKHN yapılırken, %32’sine relaps veya refrakter (R/R) hastalıktan sonra OKHN yapıldı. Tanıdan itibaren ortanca takip süresi 40 aydı (13-144 ay). Beş yıllık progresyonsuz sağkalım (PS) ve toplam sağkalım (TS) sırasıyla %50,8 ve %55,7 idi. Beş yıllık TS upfront OKHN grubunda %82,4 iken, R/R hastalarda %15,6 idi (p=0,019). OKHN öncesi TR2’de olan hastalarda ortanca TS 25 ay [%95 güven aralığı (GA): 0-50,4] iken, OKHN öncesi kısmi yanıtı olan hastalarda 13 ay (%95 GA: 0-35) idi (p=0,03). PTHL alt tiplerine göre TS ve PS tüm gruplarda istatistiksel olarak farklı saptanmadı (sırasıyla p=0,96 ve p=0,79). Sonuç: PTHL hastalarında prognoz kötü olsa dahi, TS, upfront OKHN yapılan grupta önemli oranda daha uzun saptandı. Hastalar ilk TR’de OKHN ile konsolide edilmeli ve OKHN yapmak için relaps beklenmemelidir.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.
2. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375-90.
3. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265-76.
4. Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124-30.
5. Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117:3402-8.
6. Sonnen R, Schmidt WP, Müller-Hermelink HK, Schmitz N. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol. 2005;129:366-72.
7. Moskowitz AJ, Lunning MA, Horwitz SM. How I treat the peripheral T-cell lymphomas. Blood. 2014;123:2636-44.
8. Van Heertum RL, Scarimbolo R, Wolodzko JG, Klencke B, Messmann R, Tunc F, et al. Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials. Drug Des Devel Ther. 2017;11:1719- 28.
9. Davies SM, Kollman C, Anasetti C, Antin JH, Gajewski J, Casper JT, et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program. Blood. 2000;96:4096-102.
10. Armitage JO. The aggressive peripheral T-cell lymphomas: 2015. Am J Hematol. 2015;90:665-73.
11. Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004;15:1467-75.
12. d’Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093-9.
13. Reimer P, Rüdiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27:106-13.
14. Chen AI, McMillan A, Negrin RS, Horning SJ, Laport GG. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant. 2008;14:741-7.
15. Rodríguez J, Caballero MD, Gutiérrez A, Marín J, Lahuerta JJ, Sureda A, et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol. 2003;14:1768-75.
16. Blystad AK, Enblad G, Kvaløy S, Berglund A, Delabie J, Holte H, et al. Highdose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant. 2001;27:711-6.
17. Ahn JS, Yang DH, Jung SH, Chae YS, Sohn SK, Yhim HY, et al. Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial. Ann Hematol. 2013;92:789- 97.

APA	Uncu Ulu B, ŞAHİN D, Yiğenoğlu T, Kızıl Çakar M, DAL M, Altuntas F (2021). Is the Optimal Timing First Complete Remission for Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma?. , 207 - 212. 10.4274/nkmj.galenos.2021.08108
Chicago	Uncu Ulu Bahar,ŞAHİN DERYA,Yiğenoğlu Tuğçe Nur,Kızıl Çakar Merih,DAL MEHMET SINAN,Altuntas Fevzi Is the Optimal Timing First Complete Remission for Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma?. (2021): 207 - 212. 10.4274/nkmj.galenos.2021.08108
MLA	Uncu Ulu Bahar,ŞAHİN DERYA,Yiğenoğlu Tuğçe Nur,Kızıl Çakar Merih,DAL MEHMET SINAN,Altuntas Fevzi Is the Optimal Timing First Complete Remission for Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma?. , 2021, ss.207 - 212. 10.4274/nkmj.galenos.2021.08108
AMA	Uncu Ulu B,ŞAHİN D,Yiğenoğlu T,Kızıl Çakar M,DAL M,Altuntas F Is the Optimal Timing First Complete Remission for Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma?. . 2021; 207 - 212. 10.4274/nkmj.galenos.2021.08108
Vancouver	Uncu Ulu B,ŞAHİN D,Yiğenoğlu T,Kızıl Çakar M,DAL M,Altuntas F Is the Optimal Timing First Complete Remission for Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma?. . 2021; 207 - 212. 10.4274/nkmj.galenos.2021.08108
IEEE	Uncu Ulu B,ŞAHİN D,Yiğenoğlu T,Kızıl Çakar M,DAL M,Altuntas F "Is the Optimal Timing First Complete Remission for Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma?." , ss.207 - 212, 2021. 10.4274/nkmj.galenos.2021.08108
ISNAD	Uncu Ulu, Bahar vd. "Is the Optimal Timing First Complete Remission for Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma?". (2021), 207-212. https://doi.org/10.4274/nkmj.galenos.2021.08108

APA	Uncu Ulu B, ŞAHİN D, Yiğenoğlu T, Kızıl Çakar M, DAL M, Altuntas F (2021). Is the Optimal Timing First Complete Remission for Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma?. Namık Kemal Tıp Dergisi, 9(2), 207 - 212. 10.4274/nkmj.galenos.2021.08108
Chicago	Uncu Ulu Bahar,ŞAHİN DERYA,Yiğenoğlu Tuğçe Nur,Kızıl Çakar Merih,DAL MEHMET SINAN,Altuntas Fevzi Is the Optimal Timing First Complete Remission for Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma?. Namık Kemal Tıp Dergisi 9, no.2 (2021): 207 - 212. 10.4274/nkmj.galenos.2021.08108
MLA	Uncu Ulu Bahar,ŞAHİN DERYA,Yiğenoğlu Tuğçe Nur,Kızıl Çakar Merih,DAL MEHMET SINAN,Altuntas Fevzi Is the Optimal Timing First Complete Remission for Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma?. Namık Kemal Tıp Dergisi, vol.9, no.2, 2021, ss.207 - 212. 10.4274/nkmj.galenos.2021.08108
AMA	Uncu Ulu B,ŞAHİN D,Yiğenoğlu T,Kızıl Çakar M,DAL M,Altuntas F Is the Optimal Timing First Complete Remission for Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma?. Namık Kemal Tıp Dergisi. 2021; 9(2): 207 - 212. 10.4274/nkmj.galenos.2021.08108
Vancouver	Uncu Ulu B,ŞAHİN D,Yiğenoğlu T,Kızıl Çakar M,DAL M,Altuntas F Is the Optimal Timing First Complete Remission for Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma?. Namık Kemal Tıp Dergisi. 2021; 9(2): 207 - 212. 10.4274/nkmj.galenos.2021.08108
IEEE	Uncu Ulu B,ŞAHİN D,Yiğenoğlu T,Kızıl Çakar M,DAL M,Altuntas F "Is the Optimal Timing First Complete Remission for Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma?." Namık Kemal Tıp Dergisi, 9, ss.207 - 212, 2021. 10.4274/nkmj.galenos.2021.08108
ISNAD	Uncu Ulu, Bahar vd. "Is the Optimal Timing First Complete Remission for Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma?". Namık Kemal Tıp Dergisi 9/2 (2021), 207-212. https://doi.org/10.4274/nkmj.galenos.2021.08108